Clinical Trial

Royal Jelly Supplementation in Unexplained Male Infertility

Not Yet Recruiting

Record status

This record was last updated January 13, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

This randomized, double-blind, placebo-controlled clinical trial investigates the effects of oral Royal Jelly supplementation on sperm DNA fragmentation and pregnancy rates in couples with unexplained infertility. While routine semen analysis appears normal (normozoospermia) in these patients, underlying Sperm DNA Fragmentation (SDF) and oxidative stress are believed to contribute to reproductive failure. Participants will be randomized to receive either 750 mg of lyophilized Royal Jelly or a placebo daily for a period of 3 months (90 days). The study aims to evaluate whether the antioxidant properties of Royal Jelly can improve sperm chromatin integrity, reduce oxidative stress markers, and increase spontaneous pregnancy rates compared to the control group

Trial Details

NCT Number	NCT07337265
Lead Sponsor	Medipol University
Conditions	Unexplained Infertility, Male Infertility, Sperm DNA Fragmentation
Enrollment	80 participants
Start Date	2026-02-01
Primary Completion	2026-07-01 (estimated)
Study Completion	2026-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-13